Myriad Genetics Inc (MYGN) — Institutional Investor Activity (Q2 2026)

MYGN ranks #3033 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MYGN is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

198 institutions disclose a position in MYGN, but none treat it as a major bet — even Vestal Point Capital, LP, its most concentrated holder, allocates just 0.8% of its own portfolio to it.

Assenagon Asset Management S.A. has trimmed its MYGN position for two straight quarters, cutting it by $2.5M while still holding $4.0M.

MYGN is down 8.5% today, but institutions show net buying of $83.4M this quarter — a divergence between today's price move and the underlying institutional flow.

MYGN reported a net loss of $112.6M over the trailing twelve months.

• Not yet profitable — net loss of $112.6M over the trailing twelve months
• Revenue declined 3.2% year over year
• Net income improved year over year, from -$395.2M to -$112.6M
• Generated $1.8M in positive operating cash flow
• Current ratio of 2.49x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.92x equity — within a conventional range